CytomX Therapeutics Files Proxy Statement Supplement

TL;DR

CytomX filed proxy docs, shareholders vote soon.

AI Summary

CytomX Therapeutics, Inc. filed a Definitive Additional Materials (DEFA14A) proxy statement on May 1, 2024. This filing supplements their previous proxy statement and concerns matters to be voted on by shareholders. The company is based in South San Francisco, California.

Why It Matters

This filing provides shareholders with updated information and materials related to upcoming votes, ensuring they have the necessary details to exercise their shareholder rights.

Risk Assessment

Risk Level: low — This is a routine SEC filing (DEFA14A) that supplements prior proxy materials and does not introduce new financial risks or significant operational changes.

Key Players & Entities

• CytomX Therapeutics, Inc. (company) — Registrant
• 151 Oyster Point Blvd. (location) — Company Business Address
• South San Francisco, CA (location) — Company Headquarters
• 20240501 (date) — Filing Date

FAQ

Key Financial Figures

• $0.00001 — 0,000 shares of common stock, par value $0.00001 per share. As of March 31, 2024, the Co

Filing Documents

• d734281ddefa14a.htm (DEFA14A) — 14KB
• g734281g0501080809547.jpg (GRAPHIC) — 3KB
• 0001193125-24-126170.txt ( ) — 20KB

From the Filing

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material Pursuant to 240.14a-12 CytomX Therapeutics, Inc. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): No fee required. Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. 151 Oyster Point Boulevard, Suite 400 South San Francisco, California 94080 SUPPLEMENT TO PROXY STATEMENT DATED APRIL 4, 2024 FOR THE ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON MAY 15, 2024 AT 1:00 P.M. PACIFIC TIME This Supplement to the Proxy Statement, dated May 1, 2024 (this Supplement ), supplements the definitive proxy solicitation of proxies by the Board of Directors of the Company in connection with the Annual Meeting of Stockholders to be held on May 15, 2024, at 1:00 p.m., Pacific Time by live webcast at www.virtualshareholdermeeting.com/CTMX2024 (the 2024 Annual Meeting ). Capitalized terms used in this Supplement and not otherwise defined herein have the meanings given to them in the Proxy Statement. THE PROXY STATEMENT CONTAINS IMPORTANT INFORMATION AND THIS SUPPLEMENT SHOULD BE READ IN CONJUNCTION WITH THE PROXY STATEMENT. The Proxy Statement contains various proposals, including Proposal 3, titled Approval to Amend our Amended and Restated Certificate of Incorporation to Increase the Number of Shares of Authorized Common Stock from 150,000,000 to 300,000,000 ( Proposal 3 ). This Supplement updates, and to the extent inconsistent therewith, supersedes, the disclosure in the Proxy Statement relating to Proposal 3 to clarify the total number of shares of authorized common stock remain available for issuance under the Companys Amended and Restated Certificate of Incorporation. The first paragraph in the subsection titled Summary on page 12 of the Proxy Statement in the section titled PROPOSAL 3: APPROVAL TO AMEND OUR AMENDED AND RESTATED CERTIFICATION OF INCORPORATION TO INCREASE THE NUMBER OF SHARES OF AUTHORIZED COMMON STOCK FROM 150,000,000 TO 300,000,000 is hereby revised in its entirety to read as follows: Presently, our Amended and Restated Certificate of Incorporation authorizes the issuance of 150,000,000 shares of common stock, par value $0.00001 per share. As of March 31, 2024, the Company had 68,137,635 shares of common stock issued and outstanding. As of March 31, 2024, 4,926,179 shares of common stock were reserved for issuance for future awards under our equity compensation plans, 17,774,197 shares of common stock were reserved for issuance pursuant to outstanding equity awards under our equity compensation plans, 11,538,462 shares of common stock were reserved for issuance under pre-funded warrants, and 14,423,077 shares of common stock reserved for issuance under other common stock warrants. In total, 33,200,450 shares of authorized common stock remain available for issuance. THE BOARD OF DIRECTORS RECOMMENDS THAT STOCKHOLDERS VOTE FOR THE RESOLUTION TO AMEND THE COMPANYS AMENDED AND RESTATED CERTIFICATE OF INCORPORATION TO INCREASE THE NUMBER OF SHARES OF AUTHORIZED COMMON STOCK FROM 150,000,000 TO 300,000,000. Except to the extent described in this Supplement, none of the items or information contained in the Proxy Statement are affected by this Supplement. This Supplement does not provide all of the information that is important to your voting decisions at the 2024 Annual Meeting. The Proxy Statement contains other important additional information. We encourage you to carefully read this Supplement together with the Proxy Statement in their entirety. If you were a stockholder of record on the record date for the 2024 Annual Meeting, and have already returned your proxy card or voting instruction form, you may change your vote by (1) executing and returning to the Company a later-dated proxy card, (2) resubmitting your proxy by internet or telephone, (3) delivering a written notice of revocation of your proxy to the Companys Secretary, or voting in person online during the 2024 Annual Meeting. If you are a beneficial owner, you must follow the instructions of your broker, bank or other agent to revoke your voting instructions. You may also vote in person online during the 2024 Annual Meeting if you obtain a legal proxy from your broker, bank or other nominee.

View Full Filing

View this DEFA14A filing on SEC EDGAR